S&P 500   5,051.41 (-0.21%)
DOW   37,798.97 (+0.17%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
S&P 500   5,051.41 (-0.21%)
DOW   37,798.97 (+0.17%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
S&P 500   5,051.41 (-0.21%)
DOW   37,798.97 (+0.17%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
S&P 500   5,051.41 (-0.21%)
DOW   37,798.97 (+0.17%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
$0.13
+5.2%
$0.15
$0.11
$1.28
$5.82M-0.244.70 million shs426,551 shs
Biofrontera AG stock logo
BFRA
Biofrontera
$2.60
$2.95
$2.09
$7.54
$73.73M1.0227,512 shs7,263 shs
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
$0.35
-7.7%
$1.10
$0.33
$8.17
$3.60M1.59173,534 shs364,899 shs
OptiNose, Inc. stock logo
OPTN
OptiNose
$1.09
-8.4%
$1.53
$0.90
$2.10
$122.79M-0.24535,736 shs361,422 shs
Veru Inc. stock logo
VERU
Veru
$1.26
-18.0%
$0.68
$0.36
$1.92
$183.71M-0.222.32 million shs3.20 million shs
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
-7.75%-18.57%-20.63%-19.25%-88.53%
Biofrontera AG stock logo
BFRA
Biofrontera
0.00%0.00%0.00%0.00%0.00%
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
-26.18%-46.31%-60.53%-73.59%-88.94%
OptiNose, Inc. stock logo
OPTN
OptiNose
-2.46%-10.53%-36.70%-6.30%-37.37%
Veru Inc. stock logo
VERU
Veru
+0.66%+48.54%+163.79%+267.97%+53.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
1.2404 of 5 stars
0.05.00.04.63.00.00.0
Biofrontera AG stock logo
BFRA
Biofrontera
N/AN/AN/AN/AN/AN/AN/AN/A
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
1.9543 of 5 stars
3.55.00.00.02.50.00.0
OptiNose, Inc. stock logo
OPTN
OptiNose
4.2103 of 5 stars
3.53.00.04.22.72.50.6
Veru Inc. stock logo
VERU
Veru
1.2663 of 5 stars
3.41.00.00.03.11.70.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
3.00
BuyN/AN/A
Biofrontera AG stock logo
BFRA
Biofrontera
N/AN/AN/AN/A
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
3.00
Buy$17.254,882.67% Upside
OptiNose, Inc. stock logo
OPTN
OptiNose
3.00
Buy$4.00266.97% Upside
Veru Inc. stock logo
VERU
Veru
2.75
Moderate Buy$3.33165.60% Upside

Current Analyst Ratings

Latest OPTN, MBIO, ATXI, BFRA, and VERU Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/15/2024
Veru Inc. stock logo
VERU
Veru
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$7.00 ➝ $5.00
3/28/2024
Veru Inc. stock logo
VERU
Veru
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$3.00
3/18/2024
OptiNose, Inc. stock logo
OPTN
OptiNose
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00
3/18/2024
OptiNose, Inc. stock logo
OPTN
OptiNose
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$3.00 ➝ $4.00
3/11/2024
OptiNose, Inc. stock logo
OPTN
OptiNose
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$5.00
2/8/2024
Veru Inc. stock logo
VERU
Veru
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$2.00
(Data available from 4/16/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/AN/AN/AN/A$0.03 per shareN/A
Biofrontera AG stock logo
BFRA
Biofrontera
$36.19M2.04N/AN/A$0.35 per share7.43
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
N/AN/AN/AN/A$0.01 per shareN/A
OptiNose, Inc. stock logo
OPTN
OptiNose
$70.99M1.73N/AN/A($0.77) per share-1.42
Veru Inc. stock logo
VERU
Veru
$16.30M11.27N/AN/A$0.22 per share5.70

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
-$10.38M-$1.27N/AN/AN/AN/A-335.11%5/10/2024 (Estimated)
Biofrontera AG stock logo
BFRA
Biofrontera
-$14.88M-$0.73N/AN/A-59.44%-93.31%-24.02%N/A
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
-$51.60M-$6.00N/AN/AN/A-433.08%-146.39%5/10/2024 (Estimated)
OptiNose, Inc. stock logo
OPTN
OptiNose
-$35.48M-$0.32N/AN/AN/A-50.06%N/A-33.05%5/9/2024 (Estimated)
Veru Inc. stock logo
VERU
Veru
-$93.15M-$0.75N/AN/AN/A-405.04%-257.92%-107.27%5/9/2024 (Estimated)

Latest OPTN, MBIO, ATXI, BFRA, and VERU Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/18/2024Q4 2023
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/A$0.56+$0.56$0.56N/AN/A
3/11/2024Q4 2023
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
-$1.68-$0.71+$0.97-$0.71N/AN/A
3/7/202412/31/2023
OptiNose, Inc. stock logo
OPTN
OptiNose
-$0.10-$0.09+$0.01-$0.09$19.90 million$19.87 million      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/AN/AN/AN/AN/A
Biofrontera AG stock logo
BFRA
Biofrontera
N/AN/AN/AN/AN/A
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
N/AN/AN/AN/AN/A
OptiNose, Inc. stock logo
OPTN
OptiNose
N/AN/AN/AN/AN/A
Veru Inc. stock logo
VERU
Veru
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/A
1.55
1.55
Biofrontera AG stock logo
BFRA
Biofrontera
0.13
1.26
1.13
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
N/A
0.74
0.74
OptiNose, Inc. stock logo
OPTN
OptiNose
N/A
0.60
0.55
Veru Inc. stock logo
VERU
Veru
N/A
3.21
2.79

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
17.34%
Biofrontera AG stock logo
BFRA
Biofrontera
60.07%
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
9.95%
OptiNose, Inc. stock logo
OPTN
OptiNose
85.60%
Veru Inc. stock logo
VERU
Veru
47.16%

Insider Ownership

CompanyInsider Ownership
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
1.80%
Biofrontera AG stock logo
BFRA
Biofrontera
N/A
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
2.10%
OptiNose, Inc. stock logo
OPTN
OptiNose
2.20%
Veru Inc. stock logo
VERU
Veru
14.20%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
344.26 million43.46 millionNot Optionable
Biofrontera AG stock logo
BFRA
Biofrontera
13828.36 millionN/ANot Optionable
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
8010.39 million10.17 millionNot Optionable
OptiNose, Inc. stock logo
OPTN
OptiNose
132112.65 million110.17 millionNot Optionable
Veru Inc. stock logo
VERU
Veru
189146.38 million125.60 millionOptionable

OPTN, MBIO, ATXI, BFRA, and VERU Headlines

SourceHeadline
Veru (NASDAQ:VERU) Given "Outperform" Rating at OppenheimerVeru (NASDAQ:VERU) Given "Outperform" Rating at Oppenheimer
americanbankingnews.com - April 16 at 3:26 AM
Veru (NASDAQ:VERU) Earns "Outperform" Rating from OppenheimerVeru (NASDAQ:VERU) Earns "Outperform" Rating from Oppenheimer
marketbeat.com - April 15 at 8:29 AM
Veru (NASDAQ:VERU) Stock Price Passes Above 200 Day Moving Average of $0.72Veru (NASDAQ:VERU) Stock Price Passes Above 200 Day Moving Average of $0.72
americanbankingnews.com - April 6 at 3:54 AM
REVEALED: Transport Malta officials at centre of maritime fines corruption racketREVEALED: Transport Malta officials at centre of maritime fines corruption racket
maltatoday.com.mt - April 2 at 12:43 AM
Veru Announces Date of 2024 Annual Meeting of ShareholdersVeru Announces Date of 2024 Annual Meeting of Shareholders
finance.yahoo.com - April 1 at 7:43 PM
Flag carrier Air Malta ceases operations today, its 50th birthdayFlag carrier Air Malta ceases operations today, its 50th birthday
maltatoday.com.mt - March 31 at 6:39 PM
Veru IncVeru Inc
morningstar.com - March 29 at 9:35 PM
Updated | Mosta trees vandalised: ERA, police investigatingUpdated | Mosta trees vandalised: ERA, police investigating
maltatoday.com.mt - March 29 at 8:54 AM
Raymond James Begins Coverage on Veru (NASDAQ:VERU)Raymond James Begins Coverage on Veru (NASDAQ:VERU)
marketbeat.com - March 28 at 8:28 AM
R&B Realty’s Gateway at Wynwood hit with foreclosure lawsuitR&B Realty’s Gateway at Wynwood hit with foreclosure lawsuit
therealdeal.com - March 22 at 6:18 PM
Veru Reschedules Annual Meeting of ShareholdersVeru Reschedules Annual Meeting of Shareholders
globenewswire.com - March 22 at 4:05 PM
Wynwood offices targeted in $102M foreclosureWynwood offices targeted in $102M foreclosure
bizjournals.com - March 21 at 6:43 PM
Naksha Saran plays a bike taxi driver in her next filmNaksha Saran plays a bike taxi driver in her next film
msn.com - March 19 at 4:27 AM
Precise and efficient cutting (sawing) of lightweight core materialsPrecise and efficient cutting (sawing) of lightweight core materials
jeccomposites.com - March 18 at 1:24 PM
VERU Mar 2024 0.500 putVERU Mar 2024 0.500 put
ca.finance.yahoo.com - March 16 at 1:30 PM
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight LossVeru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss
globenewswire.com - March 12 at 8:00 AM
VERU Mar 2024 1.500 putVERU Mar 2024 1.500 put
finance.yahoo.com - March 11 at 11:33 PM
Brussels is mixed bag of emotions on possible Joseph Muscat returnBrussels is mixed bag of emotions on possible Joseph Muscat return
maltatoday.com.mt - March 11 at 1:32 PM
VERU Jan 2025 17.000 callVERU Jan 2025 17.000 call
finance.yahoo.com - March 9 at 6:52 PM
VERU Mar 2024 0.500 callVERU Mar 2024 0.500 call
finance.yahoo.com - March 9 at 1:52 PM
VERU Mar 2024 3.000 putVERU Mar 2024 3.000 put
finance.yahoo.com - March 9 at 1:52 PM
VERU Mar 2024 2.500 putVERU Mar 2024 2.500 put
finance.yahoo.com - March 1 at 11:31 PM
Veru gets Nasdaq notice related to delayed quarterly report on form 10-QVeru gets Nasdaq notice related to delayed quarterly report on form 10-Q
msn.com - February 28 at 11:04 AM
Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-QVeru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q
globenewswire.com - February 27 at 7:15 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Avenue Therapeutics logo

Avenue Therapeutics

NASDAQ:ATXI
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of rare and neurologic diseases in the United States. Its lead product candidate includes AJ201, which in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous (IV) Tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. Avenue Therapeutics, Inc. was incorporated in 2015 and is based in Tampa, Florida.
Biofrontera logo

Biofrontera

NASDAQ:BFRA
Biofrontera AG engages in the development, sale and distribution of dermatological drugs and medical cosmetics for the care, protection and treatment of the skin. Its products include Ameluz, BF-RhodolesXepi and Belixos. The company was founded by Hermann Lübbert in 1997 and is headquartered in Leverkusen, Germany.
Mustang Bio logo

Mustang Bio

NASDAQ:MBIO
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clin Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.
OptiNose logo

OptiNose

NASDAQ:OPTN
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.
Veru logo

Veru

NASDAQ:VERU
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.